跳至主要内容
临床试验/NCT04351932
NCT04351932Unknown3 期

Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Randomized Non Blind Controlled Clinical Trial

Universidad Catolica Santiago de Guayaquil2 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2020年6月7日最近更新:
适应症

试验速览

阶段
3 期
发起方
入组人数
54
试验地点
2
主要终点
knee pain assessed by Visual Analogue Scale.

研究概览

简要总结

Mesenchymal stem cells (MSC) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as umbilical cord, bone marrow, and adipose tissue. The multipotent properties of MSCs make them a promising option for the treatment of osteoarthritis (OA).

Bone marrow mesenchymal stem cells (BM-MSC) and adipose derived mesenchymal stem cells (AD-MSC) have been used separately to treat OA. The aim of the present study will be to compare in a randomized non blind controlled clinical trial 3 types of intra-articular injections containing MSC populations obtained from two clinically relevant sources: BM-MSC, AD-MSC and a combination of both BM-MSC and AD-MSC.

详细描述

The aim of the present study will be to compare 3 types of intra-articular injections of MSC populations obtained from two clinically relevant sources: injections containing BM-MSC or AD-MSC or a combination of both BM-MSC,and AD-MSC in a randomized non blind clinical trial.

To assess the efficacy and safety of 3 kind of MSC injections in relation to pain, function and quality of life in patients with knee OA.

A total of 54 patients with the diagnosis of knee OA grade II and III will be recruited to receive a single intra-articular injection of MSC: Group 1 (n 18 patients) will receive BM-MSC, Group 3 (n 18 patients) will receive AD-MSC. Group 3 (18 patients) will receive a combination of BM-MSC and AD-MSC.

A randomized non blind clinical trial with active control. For this purpose, the random number generator is 54, found on the RANDOM.ORG ® website (available at https://www.random.org/integers/)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

A randomized non blind clinical trial with active control. For this purpose, the random number generator, found on the RANDOM.ORG ® website (available at https://www.random.org/integers/)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18 to 70 years, with grade II and III knee OA, according to the Ahlbäck classification will be included.
  • Minimal VAS pain score of
  • Chronic knee pain of mechanical origin.
  • All patients who sign a specially prepared informed consent for this clinical trial.

排除标准

  • Varus or valgus knee mal alignment superior to 10°.
  • OA grade IV according Ahlbäck classification.
  • Bone marrow cancer like lymphoma.
  • Severe anemia.
  • Active infections.
  • Pregnant patients.
  • Inmune diseases such as Rheumatoid arthritis, gout or pseudogout arthritis, psoriasis.
  • Bone diseases such as Kahler and Paget.
  • Corticoesteroid and hyaluronic injections within the last 3 months.
  • Knee surgery in the last 6 months.

结局指标

主要结局

knee pain assessed by Visual Analogue Scale.

时间窗: 12 months

psychometric response scale which used in questionnaires. It is a measurement instrument for subjective characteristics of pain . Score from O to 10. O indicate no pain, and 10 indicate the worst pain.

knee function assessed by WOMAC (Wester Ontario McMaster Osteoarthritis Index). quosteionary.

时间窗: 12 months

The Index contains 24 questions five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Individual question responses are assigned a score of between 0 (extreme) and 4 (None). Individual question scores are then summed to form a raw score ranging from 0 (worst) to 96 (best). Finally, raw scores are normalized by multiplying each score by 100/96. This produces a reported WOMAC Score of between 0 (worst) to 100 (best).

次要结局

  • Quantitative T2-Mapping Evaluation of Changes in Cartilage Matrix(6 months after procedure)

研究者

发起方
Universidad Catolica Santiago de Guayaquil
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Carlos Chiriboga Accini

Research Professor. Orthopaedic Staff. Omnihospital.

Universidad Catolica Santiago de Guayaquil

研究点 (2)

Loading locations...

相似试验